COVID-19 Related Codes (UB-04 Billing)
Blue Cross and Blue Shield of Kansas (BCBSKS) continues to monitor COVID-19 and the changes with billing new codes. The following new codes will be reimbursed as follows:
HCPCS Code |
Nomenclature |
MAP'd like: |
Effective Date |
Q0240 |
Injection, casirivimab and imdevimab, 600 mg |
Q0245 |
02/01/2022 |
Q0244 |
Injection, casirivimab and imdevimab, 1200 mg |
Q0245 |
02/01/2022 |
Q0220 |
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg |
Q0245 |
02/01/2022 |
M0240 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses |
M0243 |
02/01/2022 |
M0244 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the covid-19 public health emergency
|
M0241 |
02/01/2022 |
M0246 |
Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the covid-19 public health emergency
|
M0241 |
02/01/2022 |
M0248 |
Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the covid-19 public health emergency
|
M0241 |
02/01/2022 |
M0220 |
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring |
M0241 |
02/01/2022 |
M0221 |
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the covid-19 public health emergency |
M0241 |
02/01/2022 |
0051A |
Pfizer-BioNTech Covid-19 Vaccine Pre-Diluted (Gray Cap) Administration - First dose |
0013A |
02/01/2022 |
0052A |
Pfizer-BioNTech Covid-19 Vaccine Pre-Diluted (Gray Cap) Administration - Second dose
|
0013A |
02/01/2022 |
0053A |
Pfizer-BioNTech Covid-19 Vaccine Pre-Diluted (Gray Cap) Administration - Third dose |
0013A |
02/01/2022 |
0054A |
Pfizer-BioNTech Covid-19 Vaccine Pre-Diluted (Gray Cap) Administration – Booster |
0013A |
02/01/2022 |
0071A |
Pfizer-BioNTech Covid-19 Pediatric Vaccine (Orange Cap) - Administration - First dose |
0013A |
02/01/2022 |
0072A |
Pfizer-BioNTech Covid-19 Pediatric Vaccine (Orange Cap) - Administration - Second dose |
0013A |
02/01/2022 |
0073A |
Pfizer-BioNTech Covid-19 Pediatric Vaccine (Orange Cap) - Administration - Third dose |
0013A |
02/01/2022 |
91305 |
Pfizer-BioNTech Covid-19 Vaccine Pre-Diluted (Gray Cap)
|
91306 |
02/01/2022 |
91307 |
Pfizer-BioNTech Covid-19 Pediatric Vaccine (Orange Cap) |
91306 |
02/01/2022 |
If you have any questions regarding this newsletter, please contact your BCBSKS Institutional Relations provider consultant.